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ABSTRACT
Purpose. This phase I study assessed the toxicity and safety
of combining daily lapatinib with radiation therapy. Se-
quential tumor biopsies were obtained to evaluate changes
in biomarkers, such as epidermal growth factor receptor
(EGFR) and human EGFR-2 (HER2) signaling pathways.
Methods. Eligibility for this dose-escalation study in-
cluded unresectable and locally recurrent or chemotherapy-
refractory and locally advanced breast cancer, and ade-
quate organ function. Patients underwent three serial
biopsies: at baseline, after 1 week of lapatinib alone, and
after 1 week of lapatinib and radiation. Endpoints included
determination of toxicity, maximum tolerated dose, and
analysis of the effect of lapatinib with or without radiation
on EGFR and HER2 signaling pathways by immunohisto-
chemistry.
Results. Doses of lapatinib up to 1,500 mg/day were
well tolerated. Toxicity of grade 3 or more was limited to
radiation dermatitis and pain. Out of 19 patients
treated, in field responses per Response Evaluation Cri-
teria in Solid Tumors criteria were complete in four pa-
tients and partial in six patients. Serial biopsies were
obtained in 16 patients with no complications. Total
Her2 was relatively unchanged while phospho-Her2,
phospho-Akt, and phospho-ERK showed variable re-
sponses to both lapatinib alone and dual therapy with
lapatinib and radiation.
Conclusions. The combination of lapatinib and radiation
was well tolerated in this patient cohort. Overall local re-
sponse rates were comparable to those reported in other
studies in this patient population. Biopsies were safely per-
formed at all time points. Inhibition of HER2 and down-
stream signaling pathways was identified, although no
strong correlation with response was seen. The Oncologist
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INTRODUCTION
Radiation therapy plays a primary role in the treatment of pa-
tients with unresectable chest wall recurrences or chemother-
apy-refractory, locally advanced breast cancer. Yet, obtaining
adequate local control is quite difficult with local failures seen
in up to three-quarters of women treated with radiation alone
and in about half of women treated with surgical excision fol-
lowed by radiation [1–4]. Uncontrolled local-regional disease
can adversely affect quality of life, making improved local
control an important therapeutic goal [5]. Concurrent use of
chemotherapy and radiation is a commonly used approach to
improve local disease control in many cancers and has been
used in patients with breast cancer with unresectable chest wall
disease with encouraging results, but often with increased tox-
icity [6–9].
Epidermal growth factor receptor (EGFR) and its closely
related family member human epidermal growth factor recep-
tor 2 (HER2) are members of the ErbB family of growth factor
receptors. These transmembrane receptor tyrosine kinases are
involved in tumor growth and development. Through activa-
tion of a multitude of downstream signaling pathways, includ-
ing mitogen-activated protein kinases 1/2, extracellular-
signal-regulated kinases (ERK) 1/2, phosphatidylinositol
3-kinase, Akt, and nuclear factor-B, they have been impli-
cated in resistance to both chemotherapy and radiation [10–
12].
We have previously shown that inhibition of EGFR and
HER2 by lapatinib, a small molecule tyrosine kinase inhibitor
with nanomolar specificity for EGFR and its family member
HER2, acts synergistically with radiation to improve tumor
control both in vitro and in vivo in EGFR- or HER2-expressing
cells [13–15]. In addition, trastuzumab, a monoclonal antibody
targeting HER2, has shown intriguing promise as a radiosen-
sitizer in a small phase II trial at our institution [7]. Based on
preclinical data suggesting good radiosensitization with lapa-
tinib in breast cancer cell lines [13–15], this study was initiated
to evaluate the safety of combination therapy with lapatinib
and radiation, determine the recommended phase II dose, and
evaluate serial biopsies for markers of response to therapy in
patients with locally recurrent or chemotherapy-refractory, lo-
cally advanced breast cancer. Tumor biopsy samples were ob-
tained at three time points: (a) before treatment to determine
EGFR, HER2, and downstream signaling pathway activation
at baseline; (b) after 7 days of lapatinib; and (c) after 14 days of
lapatinib and 7 days of radiation. The effects on receptor acti-
vation, modulation of downstream signaling pathway, and
overall tumor proliferation were examined.
PATIENTS AND METHODS
This open-label, dose-escalation study was conducted in two
centers in North Carolina. The primary objective was to deter-
mine the recommended phase II dose of lapatinib given con-
currently with radiation. Other objectives were to evaluate the
impact of an oral EGFR/HER2 inhibitor on receptor and down-
stream signaling pathways in tumor tissue and to explore cor-
relations between response and inhibition of downstream
signaling. The study was approved by each center’s institu-
tional review board and was performed in accordance with the
Declaration of Helsinki and Good Clinical Practice.
Eligibility Criteria
Patients with unresectable, locally recurrent, or chemotherapy-
refractory locally advanced breast cancer were eligible. Dis-
ease was required to be evaluable by examination or imaging
studies and judged to be amenable to serial biopsies. Patients
were at least 18 years old, with an Eastern Cooperative Oncol-
ogy Group performance status of 0, 1, or 2; adequate hepatic,
renal, and bone marrow function; and were able to swallow
oral medication. A 3-week interval from the last systemic ther-
apy was required. Patients had to have normal left ventricular
ejection fraction (LVEF) as assessed by echocardiogram or
multigated acquisition scan. Stable brain metastases were al-
lowed. All patients gave written informed consent.
Study Assessments
Patient demographics and medical history were recorded at
baseline. Physical examination, adverse events, and tumor
measurements were assessed weekly while on combined ther-
apy, 1 month after completion of combined therapy, and every
6–8 weeks thereafter. Response was assessed per Response
Evaluation Criteria in Solid Tumors criteria [16]. Hematology
was measured at baseline and then weekly during therapy.
Multigated acquisition scan or echocardiogram was performed
8 weeks after initiating therapy and every 8 weeks while on
lapatinib.
Study Treatment and Dose Escalation
The following three sequential dose cohorts of lapatinib were
investigated in a 33 dose escalation design: 500, 1,000, and
1,500 mg orally once daily. Lapatinib alone was administered
for 1 week before starting concurrent chemoradiation. Radio-
therapy was administered in 1.8 –2.0 Gy fractions 5 days a
week, to a total dose of 35–70 Gy depending on whether the
patient had been previously irradiated. Radiotherapy fields
were based on three-dimensional conformal therapy and
planned according to standard departmental protocols. De-
pending upon tumor extent, en face electrons fields, opposed
tangential fields, three-dimensional conformal radiotherapy,
or mixed photon/electron fields were used at the discretion of
the treating radiation oncologist. Cumulative dose to the bra-
chial plexus was limited to 60 Gy. All radiation therapy plans
underwent standard quality assurance and peer review per de-
partmental protocol. Lapatinib dose modifications were based
on predefined toxicity criteria including skin rash (including
dermatitis acneiform), diarrhea leading to dehydration, and de-
creased ejection fraction.
Initially, patients were stratified based on the presence or
absence of previous radiation in the treatment field. However,
due to slower than expected patient accrual and the lack of in-
creased toxicity in the prior-radiation arm, the cohorts were
combined after completion of the 1,000-mg cohort and are pre-
sented as a single group. This study employed a typical 33
phase I dose escalation design [17]. Each dose level cohort en-
rolled three patients, with expansion to six patients if one of the
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initial three experienced a dose limiting toxicity (DLT). DLT
was defined as grade 4 hematologic toxicity; decrease in LVEF
20%; any intolerable grade 2 nonhematologic or grade 3
hematologic toxicity requiring dose reduction during com-
bined therapy; any toxicity requiring delay of therapy 2
weeks; and grade 3 acute skin toxicity using the Radiation
Therapy Oncology Group acute skin toxicity grading system
seen at doses up to 50 Gy. Of note, grade 3 skin toxicity expe-
rienced at doses above 50 Gy was expected from standard ra-
diotherapy in this clinical population and was therefore not
considered a DLT. Toxicity was assessed up to 4 weeks fol-
lowing the completion of drug.
Enrollment in the subsequent cohort began after all patients
in the preceding cohort had completed treatment. If more than
two of six patients experienced DLT, then the maximum tol-
erated dose had been exceeded and enrollment continued at the
lower dose level until a total of six patients had been enrolled at
that dose. No intrapatient dose escalation was allowed. The
recommended phase II dose was defined as the dose of lapa-
tinib with radiation, at which no more than one out of six pa-
tients experienced a DLT.
Tumor Biopsies
Tumor biopsy, obtained by skin punch or core biopsy, was per-
formed serially: at baseline, after 1 week of lapatinib alone
(day 8), and after 1 week of lapatinib and radiation (day 15).
Biopsies were saved on saline soaked gauze, fixed in 10% neu-
tral buffered formalin for 48 hours, dehydrated in graded alco-
hol solutions, and embedded in paraffin.
Immunohistochemistry
Paraffin-embedded tissues were sectioned at 5 m and immu-
nohistochemistry (IHC) was performed according to the indi-
vidual antibody manufacturer’s instructions in the University
of North Carolina Anatomic Pathology Research Core Labo-
ratory. Briefly, tissue sections were deparaffined with xylene;
dehydrated with 100%, 95%, and 70% ethanol; and endoge-
nous peroxidase activity was blocked with 3% hydrogen per-
oxidase with methanol. Samples were steamed for antigen
retrieval with 10 mM citrate buffer (pH 6.0) for 30 minutes,
blocked with blocking serum, incubated with biotinylated an-
tibody, and incubated with streptavidin conjugated horseradish
peroxidase using Vectastain ABC kit (Vector Laboratories,
Burlingame, CA) per the manufacturer’s protocol. Slides were
counterstained with hematoxylin and examined by light mi-
croscopy. Positive and negative controls were processed si-
multaneously to validate appropriate binding. When
necessary, IHC procedures were optimized using control tis-
sues. A variety of antibody sources and conditions were used
(supplemental online Table 1) and IHC was performed for
EGFR, phospho-EGFR, HER2, phospho-HER2, Akt, phos-
pho-Akt, ERK, phospho-ERK, tumor protein 53, and estrogen
receptor. Proliferation was assessed by Ki-67 and the percent-
age of positive cells was determined as the Ki-67 index. When
sufficient tissue was available, IHC was performed at all time
points.
For all samples, IHC was scored for both intensity and per-
centage of tumor staining by a single breast pathologist
(C.A.L.) and by one of the investigators (R.J.K.). Analysis of
tumor biopsies was performed by calculating an H-score in-
cluding percentage and intensity of staining [18]. Comparison
between baseline (biopsy 1), postlapatinib (biopsy 2), and
postradiation (biopsy 3) biopsies was performed by grouping
those with increased, unchanged, and decreased H-scores.
Standardized HER2 and estrogen receptor expression from
each patient’s original biopsy were abstracted from the pathol-
ogy report [19] and compared to staining on repeat biopsies.
All analyses were conducted with SAS statistical software,
version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
A total of 21 patients were enrolled; 7, 9, and 3 patients were
included in the 500-, 1,000-, and 1,500-mg cohorts, respec-
tively. Two patients did not receive protocol-directed therapy
due to withdrawal prior to beginning radiation (symptomatic
pulmonary disease and personal choice). Baseline characteris-
tics (Table 1) and the enrollment diagram (Fig. 1) are shown.
The 500-mg cohort was expanded to seven patients because
one patient had disease that was judged after enrollment to not
be amenable to biopsy. This patient was assessable for toxicity
endpoints of the trial but not correlative biopsies. One patient
discontinued lapatinib and radiation after receiving only 44 Gy
because of progressive disease both within and outside the ra-
diation field, but was included in the analysis. All other pa-
tients completed the prescribed course of therapy.
Table 1. Patient characteristics at baseline (n  19)
Characteristic n (%)










Unknown/not done 2 (10)
Previous radiation therapy 6 (32)
Previous chemotherapy 17 (89)
Cutaneous disease only 11 (58)
Markers
ER positive 8 (42)
PR positive 3 (16)
HER2 positive 8 (42)
Triple negative 7 (37)
Abbreviations: ER, estrogen receptor; PR, progesterone
receptor.
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Patients who had not received prior irradiation received a
median dose of 60 Gy (range, 44–70 Gy). Previously irradi-
ated patients received a median dose of 50 Gy (range, 45–70.2
Gy). In patients who had received prior irradiation, higher ra-
diation doses were usually given to areas outside the prior
treatment fields. No treatment breaks were needed and no dose
reductions were made.
Maximally Tolerated Dose
Patients were initially treated with lapatinib at 500 mg/day,
with escalations to 1000 mg/day, and 1,500 mg/day. At the
500-mg dose, no patients experienced a DLT. At the 1,000-mg
dose, one patient who had not been previously irradiated ex-
perienced a DLT (grade 3 moist desquamation developed at 48
Gy). This cohort was expanded by three additional patients. No
additional DLTs were observed in this cohort or in the three
patients who had been previously irradiated and were treated at
the 1,000-mg dose level. As the 1,000-mg dose level was found
to be safe regardless of prior radiation, the two arms were com-
bined for the final 1,500-mg cohort. None of the three patients
in the final 1,500-mg cohort experienced a DLT. MTD was not
reached at the dose approved by the U.S. Food and Drug Ad-
ministration for the single-agent lapatinib.
Toxicity
The most common toxicities reported during study treatment,
regardless of causality, are listed in Table 2. The majority of
toxicities were grade 1 (Fig. 2). Gastrointestinal toxicity was
minor, with six patients reporting grade 1 or 2 diarrhea, five
with grade 1 or 2 nausea, and three with grade 1 or 2 vomiting.
Most grade 3 toxicities were radiation dermatitis, an expected
effect of radiation in patients with locally advanced or locally
recurrent breast cancer. No cases of grade 3 acneiform rash
were reported, although six patients had grade 1 or 2 rash. No
grade 4 toxicities were reported and no patient developed
symptomatic cardiac dysfunction.
Response
Although not the primary objective of this phase I study, some
degree of in-field response was seen in 10 of 19 patients. Two
patients had progressive disease and seven had stable disease
at the conclusion of treatment.
Serial Tumor Biopsies
Successful serial core biopsies were obtained at all three time
points for 16 of 21 patients. Two patients had disease that was
not able to be biopsied at the initial time point despite being
judged amenable to biopsy at the initial screening, so they did
not undergo serial biopsies. One additional patient did not un-
dergo the third planned biopsy after being hospitalized for pain
control. No complications were observed as a result of the se-
rial biopsies. Three patients had all three biopsies performed
but did not have sufficient viable tumor present for analysis at
any time point. Samples from one patient were unusable due to
difficulties with transport of biopsy material. Seven additional
patients had insufficient tissue available for completion of all
IHC studies. IHC analyses were performed using a prioritiza-
tion schema when tissue resources did not permit all analyses
to be performed (supplemental online Table 2). Six serial sam-
ples were evaluable for the assessment of changes in all sig-
naling pathways at all time points.
Baseline Assessment of Signaling Pathways
Pretreatment biopsies were analyzed for expression of EGFR,
phospho-EGFR, HER2, phospho-HER2, phospho-Akt, phos-
pho-ERK, Ki-67, and p65. EGFR expression was seen in 3 of
12 patients. Insufficient samples were available to analyze
EGFR activation via phospho-EGFR staining. Four patients
were found to be HER2-positive by clinical testing (3 stain-
ing in more than 10% of cells or positive by in situ hybridiza-
tion). Either HER2 or phospho-HER2 expression was seen in 9
of 11 patients (Table 3), although not always in sufficient in-
tensity to qualify as positive by clinical criteria. No significant
relationship between phospho-HER2 at baseline and clinical
response was identified. Phospho-Akt was seen in 8 of 10 pa-
tients, whereas phospho-ERK was seen in 9 of 10 patients (Ta-
ble 3). At baseline, 10 patients were evaluable for Ki-67:
respectively, seven, one, and two patients had Ki-67 indexes of
25%, 10%–25%, and 10%. p65 staining was seen in seven
of nine patients.
Post-treatment Assessment of Signaling Pathways
Based on preclinical in vitro work, we expected lapatinib to re-
sult in downregulation of HER2 activation [14]. Following 1
week of lapatinib treatment, total HER2 was unchanged in six
of nine patients and phospho-HER2 staining was decreased in
four of six patients, three of whom had a clinical response to
chemoradiation (Table 3). No biopsy pair showed a decrease in
Figure 1. Consolidated Standards of Reporting Trials diagram.
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phospho-Akt, but three of seven patients (all of whom had a
partial response to treatment) demonstrated increased phos-
pho-Akt following lapatinib (Table 3). Phospho-Erk activation
was decreased in three of seven patients (Table 3), two of
whom had a response to therapy and one who had progressive
disease. The Ki-67 index decreased in two of eight patients fol-
lowing lapatinib alone.
Comparison of biopsies taken at baseline with those taken
after 1 week of combined lapatinib and radiation showed little
change in total EGFR. Decreased total HER2 was seen in two
patients who had no response to therapy, whereas no change in
HER2 was seen in five patients who had a response to therapy
(Table 3). Decreased phospho-HER2 was seen in three of eight
patients, with the most striking differences seen in patients
with clinical responses (Fig. 3, Table 3). As expected based on
preclinical work [13, 14], decreased phospho-ERK was seen in
three of seven patients, and decreased phospho-Akt was seen
in four of seven patients, respectively (Table 3). The Ki-67 in-
dex decreased from baseline in four of eight patients following
chemoradiation. Seven of the 16 patients did not have suffi-
cient tissue present in the third biopsy to allow meaningful
comparisons with earlier time points due to the absence of vi-
able tumor within the sample tissue.
DISCUSSION
This study showed that lapatinib given at 1,500 mg/day with
chest wall radiation was well tolerated in patients with unre-
sectable chest wall recurrences or chemotherapy-refractory,
locally advanced breast cancer. There were no DLTs in the
1,500 mg dose escalation cohort, albeit with a small number of
patients treated. Further expansion was precluded due to poor
accrual and insufficient funds. The entire planned course of ra-
diation was delivered in all but one patient who developed pro-
gressive disease within the radiation field leading to the
decision to cease therapy on trial. The recommended phase II
dose (1,500 mg/day) was the same as the MTD determined by
Harrington et al. in their phase I study in patients with locally
advanced squamous cell carcinoma of the head and neck
treated with lapatinib and concurrent radiation [20].
Patients with local-regional recurrence after mastectomy
have a poor prognosis; 5-year survival rates are routinely less
than 50% [21, 22]. Uncontrolled local-regional disease is
highly morbid [3] and has been associated with worse survival
(35% vs. 64% at 5 years) compared to those patients whose lo-
cal-regional disease is controlled [23]. Local control rates with
radiation alone, the current standard of care, have been in the
range of 30%–60% [1, 4, 21, 23–24]. Not surprisingly, several
of these series suggested that tumors treated to higher radiation
doses had improved local control [1, 4, 21, 23]. However, im-
proved local control comes at the risk of increased toxicity and
wound healing complications [25], and it is often limited in the
setting of prior irradiation.
The best-studied radiation sensitizer for chest wall recur-
rence is hyperthermia, which has been the subject of five ran-
domized trials. Although studies have been plagued by poor
accrual, in a combined analysis, hyperthermia has been shown
to improve local control at the expense of increased toxicity
[26]. Because of the resources involved in delivering hyper-
thermia (cost, equipment, time, and personnel), this is not an
Table 2. Adverse events of any grade reported in 5% of patients during study treatment regardless of causality
Adverse event (n)
Lapatinib 500 mg (n  7) Lapatinib 1,000 mg (n  9) Lapatinib 1,500 mg (n  3) All patients (n  19)
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
Radiation dermatitis 2 1 1 5 1 2 1 7
Acneiform rash 1 3 5 0 0
Pruritus 1 1 2 0 0
Oral mucositis 1 1 0 0




3 1 1 5 0 0
Vomiting 2 1 3 0 0
Nausea 1 4 5 0 0
Dyspnea 1 0 1 0
Fatigue 2 3 1 2 4 0
Lymphatic edema 1 2 1 4 0 0
Pain 2 0 0 2
Any 9 1 1 19 5 7 5 2 1
A patient may have had more than one event.
Figure 2. Toxicity profile.
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option at the majority of radiation oncology centers. In many
other disease sites, concurrent chemotherapy and radiation are
used as standard therapy to improve local control and survival.
However, data supporting chemoradiation in breast cancer are
limited to several phase I and small phase II trials. Formenti et
al. used twice-weekly paclitaxel and concurrent radiation in
women with operable stage IIB–III breast cancer with minimal
grade 3 skin desquamation (7%) and a 34% pathologic com-
plete remission rate [27]. Chakravarthy et al. found a 34% patho-
logic complete response rate and a low rate of grade 3 or 4 toxicity
in a small cohort of patients with operable breast cancer treated
with neoadjuvant paclitaxel and radiation [28]. Suh et al. at the
University of Michigan reported on a phase I trial investigating
the use of gemcitabine with radiation for patients with unresect-
able chest wall recurrences; they reported grade 3 neutropenia in
two of three patients treated at the initial dose level and grade 3 or
Table 3. Immunohistochemistry score by patient for HER2, phospho-ERK, and phospho-AKT
Patient
HER2 pHER2 pAKT pERK
Infield
responseBaseline Biopsy 2 Biopsy 3 Baseline Biopsy 2 Biopsy 3 Baseline Biopsy 2 Biopsy 3 Baseline Biopsy 2 Biopsy 3
1 3  3 Increased Decreased 0  0 Unchanged Unchanged 3  1 Unchanged Decreased 3  4 Unchanged Unchanged SD
2 0  0 Unchanged Unchanged 2  3 Decreased Decreased 2  1 Increased Increased 3  4 Decreased Unchanged PR
3 0  0 NE Unchanged 2  3 NE Unchanged 2  3 NE Decreased 3  4 NE Unchanged PR
4 NE NE NE NE NE NE NE NE NE NE NE NE PD
5 3  4 Unchanged Unchanged 2  1 Decreased Increased 3  4 Unchanged Unchanged 3  1 Decreased Decreased CR
6 0  0 Unchanged Unchanged 2  3 Decreased Decreased 3  0 Increased Decreased 3  2 Unchanged Unchanged PR
7 0  0 Unchanged NE 0  0 Increased NE 0  0 Unchanged NE 3  3 Unchanged NE SD
8 0  0 Increased Decreased 2  1 Decreased Decreased 2  1 Unchanged Unchanged 3  2 Decreased Decreased PD
9 NE NE NE NE NE NE NE NE NE NE NE NE PR
10 0  0 Unchanged NE 0  0 NE NE NE NE NE NE NE NE PR
11 NE NE NE NE NE NE NE NE NE NE NE NE CR
12 2  2 Decreased Unchanged 3  4 Unchanged Unchanged NE NE NE NE NE NE CR
13 3  4 Unchanged Unchanged 0  0 Unchanged Unchanged 2  3 Increased Decreased 3  1 Unchanged Decreased PR
14 3  4 Ne NE 0  0 NE NE 0  0 NE NE 3  2 NE NE SD
15 NE Ne NE NE NE NE NE NE NE NE NE NE SD
16 NE Ne NE NE NE NE 3  4 NE NE NE NE NE SD
First number represents staining intensity (0  negative, 1  borderline, 2  weak, 3  moderate) and second number
represents the percentage of cells positive (0  10%, 1  10%–25%, 2  26%–50%, 3  51%–75%, 4  75%).
Change in H-score between baseline and biopsy 2 and biopsy 3 indicated.
Abbreviations: CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.
Figure 3. Representative micrographs showing phosphoHER2 staining at baseline (left), after 1 week of lapatinib (middle), and after 1
week of radiation and 2 weeks of lapatinib (right). Abbreviation: RT, radiotherapy.
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4 acute skin toxicity in all patients [6]. Our study was designed
based on promising preclinical data regarding the efficacy of lapa-
tinib as a breast cancer radiosensitizer [13, 15] and with the hope
that the use of a dual EGFR/HER2 targeted inhibitor would be
more tolerable than standard systemic therapy.
The toxicity profile in this study was consistent with what we
have previously seen in a phase II trial investigating concurrent
trastuzumab and radiation in a similar cohort of patients [7]. Ac-
neiform rash was seen in approximately 30% of patients in this
study. Although definitive conclusions are limited by sample size,
the rate did not increase with lapatinib dose escalation. This is
similar to what was reported by Harrington et al. [20] and was in
the range of the 43% rate reported in a recent analysis of nine clin-
ical trials using lapatinib monotherapy [29].
Although the small size of our trial limited our ability to
investigate the association of rash with response, there is a
growing body of evidence suggesting that rash is not predictive
of response in all EGFR inhibitors [20, 30]. Consistent with
what has been reported in other investigations of lapatinib, di-
arrhea was seen in about 30% of patients, was mild in all cases
with no grade 3 or higher toxicity seen, and was successfully
managed with conservative therapy according to standard
guidelines [31]. Cardiac events have been seen less frequently
with lapatinib than with the HER2 monoclonal antibody tras-
tuzumab, perhaps suggesting different pathologic mecha-
nisms. We did not see any cases of left ventricular dysfunction
in the patients treated on this study despite the frequency of
prior treatment with cardiotoxic drugs (i.e., trastuzumab and
adriamycin) in a number of patients.
Performing serial tumor biopsies in irradiated tissue can be
safely accomplished and may provide valuable information
confirming in vitro-generated hypotheses, identifying prog-
nostic or predictive markers, and identifying new avenues of
investigation [32]. However, this study also highlights the in-
herent difficulty in obtaining serial biopsies in this manner: a
significant number of biopsies contained scant or no tumor tis-
sue, which not only limits the accuracy of scoring, but also may
lead to underappreciation of intratumoral heterogeneity.
Although we were able to detect changes in downstream
pathways, the semiquantitative nature of IHC made it difficult
to identify predictors of response in this small dose-escalation
study. We did see results that appeared similar to those de-
scribed by Spector et al. from a small clinical study: relatively
unchanged total HER2 and variable changes in phospho-
HER2, phospho-Akt, and phospho-ERK [33]. Interestingly,
we did not identify the patterns of change predicted by our in
vitro work [13–15]. These differences between in vitro analy-
sis and patient biopsies may have several explanations, includ-
ing the small sample size of our study, changes in molecular
responses that occur between 1 day (in vitro studies) and 1
week (clinical trial) after therapy, heterogeneity in patient tu-
mors, or even fundamental differences between drug responses
in patient tumors and cell lines maintained in vitro. It may be
that serial biopsy analysis of this type may be best used in
larger phase II trials or within the confines of an expanded dose
cohort in a phase I trial.
CONCLUSION
Lapatinib (1,500 mg/day), when given concurrently with radi-
ation to patients with unresectable chest wall recurrences or
chemotherapy-refractory, locally advanced breast cancer, was
well tolerated. This dose was associated with an acceptable tol-
erability profile, similar to that observed with radiation alone
for treatment of this disease; it resulted in a nearly 50% re-
sponse rate. Further studies investigating rational combina-
tions of targeted therapy and radiation for women with locally
advanced breast cancer are warranted.
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